268 related articles for article (PubMed ID: 27107895)
21. An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer.
Sun G; Wang C; Wang S; Sun H; Zeng K; Zou R; Lin L; Liu W; Sun N; Song H; Liu W; Zhou T; Jin F; Shan Z; Zhao Y
Nucleic Acids Res; 2020 Nov; 48(19):10768-10784. PubMed ID: 32986841
[TBL] [Abstract][Full Text] [Related]
22. ERE-independent ERalpha target genes differentially expressed in human breast tumors.
Glidewell-Kenney C; Weiss J; Lee EJ; Pillai S; Ishikawa T; Ariazi EA; Jameson JL
Mol Cell Endocrinol; 2005 Dec; 245(1-2):53-9. PubMed ID: 16298037
[TBL] [Abstract][Full Text] [Related]
23. ERα promotes transcription of tumor suppressor gene
Wang B; Shen Y; Liu T; Tan L
J Zhejiang Univ Sci B; 2021 Dec; 22(12):1034-1044. PubMed ID: 34904415
[TBL] [Abstract][Full Text] [Related]
24. RhoA and RhoC differentially modulate estrogen receptor α recruitment, transcriptional activities, and expression in breast cancer cells (MCF-7).
Malissein E; Meunier E; Lajoie-Mazenc I; Médale-Giamarchi C; Dalenc F; Doisneau-Sixou SF
J Cancer Res Clin Oncol; 2013 Dec; 139(12):2079-88. PubMed ID: 24096540
[TBL] [Abstract][Full Text] [Related]
25. PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor α-Positive Breast Cancer Cells.
Gadad SS; Camacho CV; Malladi V; Hutti CR; Nagari A; Kraus WL
Mol Cancer Res; 2021 Oct; 19(10):1688-1698. PubMed ID: 34158394
[TBL] [Abstract][Full Text] [Related]
26. SnoN oncoprotein enhances estrogen receptor-α transcriptional activity.
Band AM; Laiho M
Cell Signal; 2012 Apr; 24(4):922-30. PubMed ID: 22227247
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.
Normanno N; Di Maio M; De Maio E; De Luca A; de Matteis A; Giordano A; Perrone F;
Endocr Relat Cancer; 2005 Dec; 12(4):721-47. PubMed ID: 16322319
[TBL] [Abstract][Full Text] [Related]
28. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L
Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130
[TBL] [Abstract][Full Text] [Related]
29. Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.
Yu L; Wang L; Mao C; Duraki D; Kim JE; Huang R; Helferich WG; Nelson ER; Park BH; Shapiro DJ
Cancer Lett; 2019 Feb; 442():373-382. PubMed ID: 30419347
[TBL] [Abstract][Full Text] [Related]
30. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
31. Cyclin dependent kinase-9 mediated transcriptional de-regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers.
Sengupta S; Biarnes MC; Jordan VC
Breast Cancer Res Treat; 2014 Jan; 143(1):113-24. PubMed ID: 24309997
[TBL] [Abstract][Full Text] [Related]
32. Ctr9, a key subunit of PAFc, affects global estrogen signaling and drives ERα-positive breast tumorigenesis.
Zeng H; Xu W
Genes Dev; 2015 Oct; 29(20):2153-67. PubMed ID: 26494790
[TBL] [Abstract][Full Text] [Related]
33. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
[TBL] [Abstract][Full Text] [Related]
34. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
[TBL] [Abstract][Full Text] [Related]
35. USP9X downregulation renders breast cancer cells resistant to tamoxifen.
Oosterkamp HM; Hijmans EM; Brummelkamp TR; Canisius S; Wessels LF; Zwart W; Bernards R
Cancer Res; 2014 Jul; 74(14):3810-20. PubMed ID: 25028367
[TBL] [Abstract][Full Text] [Related]
36. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
Kim SS; Lee MH; Lee MO
Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
[TBL] [Abstract][Full Text] [Related]
37. The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer.
Magnani L; Patten DK; Nguyen VT; Hong SP; Steel JH; Patel N; Lombardo Y; Faronato M; Gomes AR; Woodley L; Page K; Guttery D; Primrose L; Fernandez Garcia D; Shaw J; Viola P; Green A; Nolan C; Ellis IO; Rakha EA; Shousha S; Lam EW; Győrffy B; Lupien M; Coombes RC
Oncotarget; 2015 Sep; 6(26):21878-91. PubMed ID: 26215677
[TBL] [Abstract][Full Text] [Related]
38. Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.
Singh K; Munuganti RSN; Lallous N; Dalal K; Yoon JS; Sharma A; Yamazaki T; Cherkasov A; Rennie PS
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462880
[TBL] [Abstract][Full Text] [Related]
39. Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.
Pescatori S; Leone S; Cipolletti M; Bartoloni S; di Masi A; Acconcia F
J Exp Clin Cancer Res; 2022 Apr; 41(1):141. PubMed ID: 35418303
[TBL] [Abstract][Full Text] [Related]
40. Estrogen Receptor-β Modulation of the ERα-p53 Loop Regulating Gene Expression, Proliferation, and Apoptosis in Breast Cancer.
Lu W; Katzenellenbogen BS
Horm Cancer; 2017 Aug; 8(4):230-242. PubMed ID: 28577282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
